Atlantic Trust Group LLC bought a new stake in Omnicell, Inc. (NASDAQ:OMCL) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 40,716 shares of the company’s stock, valued at approximately $2,079,000. Atlantic Trust Group LLC owned approximately 0.11% of Omnicell as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Marco Investment Management LLC bought a new stake in Omnicell during the third quarter worth $231,000. California Public Employees Retirement System lifted its holdings in Omnicell by 6.2% during the third quarter. California Public Employees Retirement System now owns 86,240 shares of the company’s stock worth $4,403,000 after acquiring an additional 5,040 shares during the period. Janney Capital Management LLC lifted its holdings in Omnicell by 45.3% during the third quarter. Janney Capital Management LLC now owns 9,484 shares of the company’s stock worth $484,000 after acquiring an additional 2,957 shares during the period. Synovus Financial Corp lifted its holdings in Omnicell by 8.4% during the third quarter. Synovus Financial Corp now owns 21,009 shares of the company’s stock worth $1,079,000 after acquiring an additional 1,623 shares during the period. Finally, Pier Capital LLC bought a new stake in Omnicell during the third quarter worth $5,488,000. Institutional investors own 99.61% of the company’s stock.
A number of analysts recently commented on the company. Zacks Investment Research lowered Omnicell from a “hold” rating to a “sell” rating in a report on Wednesday. BidaskClub lowered Omnicell from a “hold” rating to a “sell” rating in a report on Friday, December 22nd. Cantor Fitzgerald reiterated a “buy” rating and set a $60.00 price target on shares of Omnicell in a report on Wednesday, December 13th. Craig Hallum reiterated a “buy” rating and set a $62.00 price target (up from $52.00) on shares of Omnicell in a report on Monday, October 30th. Finally, Oppenheimer reiterated a “buy” rating and set a $55.00 price target on shares of Omnicell in a report on Tuesday, December 5th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. Omnicell currently has an average rating of “Hold” and a consensus target price of $55.14.
In other news, VP Jorge R. Taborga sold 6,295 shares of Omnicell stock in a transaction on Monday, November 6th. The stock was sold at an average price of $48.69, for a total value of $306,503.55. Following the completion of the transaction, the vice president now directly owns 50,013 shares in the company, valued at $2,435,132.97. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Dan S. Johnston sold 14,613 shares of Omnicell stock in a transaction on Friday, November 17th. The shares were sold at an average price of $47.81, for a total value of $698,647.53. Following the completion of the transaction, the executive vice president now owns 43,621 shares of the company’s stock, valued at $2,085,520.01. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,558 shares of company stock worth $1,330,230. Corporate insiders own 3.77% of the company’s stock.
Shares of Omnicell, Inc. (NASDAQ:OMCL) opened at $50.75 on Friday. The stock has a market capitalization of $1,913.69, a price-to-earnings ratio of -461.36, a price-to-earnings-growth ratio of 4.00 and a beta of 0.71. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.08. Omnicell, Inc. has a one year low of $32.35 and a one year high of $55.40.
Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42. The firm had revenue of $186.78 million for the quarter, compared to analyst estimates of $192.45 million. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The business’s revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.40 earnings per share. equities research analysts predict that Omnicell, Inc. will post 0.12 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/14/atlantic-trust-group-llc-purchases-new-position-in-omnicell-inc-omcl.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.